A novel 48-mm stent for the treatment of diffuse de novo coronary artery lesions was found to be safe and effective at 1 year, with a high level of device deliverability, a speaker reported.The results of the prospective, single-arm, open-label, multicenter global SPIRIT 48 trial were presented at the Society for Cardiovascular Angiography and Interventions Scientific Sessions and simultaneously